That must change, as standardization is essential for low burden mutations with clinical impacts (e.g., TP53 mutations in several hematological neoplasms (CLL or myelodysplastic syndromes, MDS)), the follow-up of minimal residual disease, or the detection of clonal hematopoiesis or circulating nucleic acids in sera or plasma. The gene discussed is TP53; the disease is myelodysplastic syndrome.